Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

46.50
+1.663.70%
Volume:2.16M
Turnover:100.26M
Market Cap:7.73B
PE:-13.36
High:47.42
Open:46.68
Low:45.76
Close:44.84
52wk High:86.74
52wk Low:44.66
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.54
T/O Rate:1.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:17.57
PE(LYR):-19.53

Loading ...

Ionis Pharmaceuticals Inc: on Track to Achieve 2026 Financial Guidance

THOMSON REUTERS
·
Jul 29

Movement Alert|Ionis Pharmaceuticals Rises 5.39% in Regular Trading, Trading at $56.92

Market Focus
·
Jul 23

US High Growth Tech Stocks to Watch for Potential Expansion

Simply Wall St.
·
Jul 23

Earning Preview: Ionis Pharmaceuticals Q2 revenue is expected to decrease by 35.92%, and institutional views are cautious

Earnings Agent
·
Jul 23

Movement Alert|Ionis Pharmaceuticals Falls 5.16% in Regular Trading, Cardiovascular Pipeline Setback and Pre-Earnings Caution Weigh on Shares

Market Focus
·
Jul 22

Movement Alert|Ionis Pharmaceuticals Falls 6.35% in Pre-Market Trading, Bearish Sentiment Ahead of Earnings Compounded by Pipeline Setback

Market Focus
·
Jul 22

Ionis Pharmaceuticals is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 21

Ionis Pharmaceuticals Inc : Guggenheim Cuts Target Price to $89 from $106

THOMSON REUTERS
·
Jul 21

Ionis Pharmaceuticals Cut to Peer Perform from Outperform by Wolfe Research

Dow Jones
·
Jul 16

Wolfe cuts Ionis Pharma to Peer Perform after disappointing trial data

TIPRANKS
·
Jul 16

Ionis Pharmaceuticals call volume above normal and directionally bullish

TIPRANKS
·
Jul 16

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 15

Press Release: Ionis to Hold Second Quarter 2026 Financial Results Webcast

Dow Jones
·
Jul 15

Ionis Pharmaceuticals Schedules Webcast on Second-quarter 2026 Results

Reuters
·
Jul 15

Ionis Partner Biogen Presents Phase 2 Celia Data at Aaic Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

THOMSON REUTERS
·
Jul 14

Ionis Pharmaceuticals is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 13

Ionis Doses First Patient in Phase 1-2 Trial of Ion337 for Dravet Syndrome

Reuters
·
Jul 13

Ionis Doses First Participant in Phase 1-2 Ascend Study of Ion337 in Dravet Syndrome

THOMSON REUTERS
·
Jul 13

RBC Cuts Price Target on Ionis Pharmaceuticals to $85 From $100, Keeps Outperform Rating

MT Newswires Live
·
Jul 13

Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's?

Dow Jones
·
Jul 13